915 results on '"O'Rourke, Robert A."'
Search Results
152. Abstract P323: Comparison and Validation of Quality of Life Instruments in Optimally-Treated Stable Coronary Patients
153. Abstract P173: Risk Factor Analysis of Clinically Significant Improvements in Quality of Life Measures for Stable Coronary Patients
154. Abdominal pain after gastric bypass: suspects and solutions
155. Prevalence of Adverse Intraoperative Events During Obesity Surgery and Their Sequelae
156. HIGH-DENSITY LIPOPROTEIN (HDL) CHOLESTEROL IS ASSOCIATED WITH RESIDUAL RISK OF CARDIOVASCULAR EVENTS IN PATIENTS WITH STABLE ISCHEMIC HEART DISEASE DESPITE OPTIMAL LEVELS OF LOW-DENSITY LIPOPROTEIN (LDL) CHOLESTEROL: A POST HOC ANALYSIS FROM THE COURAGE TRIAL
157. A NEW RISK PREDICTION TOOL TO ASSESS LONG-TERM PROGNOSIS IN PATIENTS WITH STABLE ISCHEMIC HEART DISEASE (SIHD): THE “COURAGE RISK SCORE”
158. Management Strategies for Internal Hernia after Gastric Bypass
159. Is Optimal Medical Therapy as Used in the COURAGE Trial Feasible for Widespread Use?
160. Alternative Strategies for the Management of Chronic Stable Angina
161. 595 Functional Lumen Imaging Probe to Assess Geometric Changes in the Esophagogastric Junction Following Endolumenal Fundoplication
162. IMPACT OF PRETREATMENT ISCHEMIA ON THERAPEUTIC RISK REDUCTION AND LONG-TERM PROGNOSIS IN PATIENTS WITH STABLE ANGINA: RESULTS FROM COURAGE TRIAL
163. Intensive Multifactorial Intervention for Stable Coronary Artery Disease
164. Optimal Medical Therapy With or Without Percutaneous Coronary Intervention in Older Patients With Stable Coronary Disease
165. Quantitative Results of Baseline Angiography and Percutaneous Coronary Intervention in the COURAGE Trial
166. T2079 Pneumoperitoneum in NOTES: Examining the Physiologic Effects of Sequential Endoluminal and Intraperitoneal Insufflation
167. PL-109: A comparison of 30 day outcomes after primary and revisional bariatric surgical procedures from the longitudinal assessment of bariatric surgery (LABS) study
168. Mitral Regurgitation
169. Inflammation in obesity-related diseases
170. The Evolving Pattern of Symptomatic Coronary Artery Disease in the United States and Canada: Baseline Characteristics of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) Trial
171. Response to Letters Regarding Article, “Optimal Medical Therapy With or Without Percutaneous Coronary Intervention to Reduce Ischemic Burden: Results From the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial Nuclear Substudy”
172. Appendix: Update on Coronary Artery Bypass Surgery: Current and Future Trends
173. Abstract 6225: Cost of Improvement of Angina-Related Health Status by Health Care System: A Secondary Analysis from the COURAGE Trial
174. Cost-Effectiveness of Percutaneous Coronary Intervention in Optimally Treated Stable Coronary Patients
175. ACC/AHA 2008 Guideline Update on Valvular Heart Disease: Focused Update on Infective Endocarditis
176. Foreword
177. Transoral Endoscopic Fundoplication in the Treatment of Gastroesophageal Reflux Disease
178. In Memoriam: W. Proctor Harvey, MD
179. S1109 Use of the Functional Lumen Imaging Probe (FLIP) to Determine Structural Changes in the Region of the Esophagogastric Junction After Endoluminal Fundoplication Using Esophyx® for GERD
180. 777 Tailored Transoral Incisionless Fundoplication (TIF) in the Treatment of GERD: the Anatomic and Physiologic Basis for Reconstruction of the Esophagogastric Junction Using a Novel Approach
181. 952 VEGF Gene Therapy Improves Anastomotic Healing in the Gastrointestinal Tract: Applications in Esophageal Surgery
182. Optimal Medical Therapy With or Without Percutaneous Coronary Intervention to Reduce Ischemic Burden
183. The Corrected Values for Duration and Frequency of Angina at Baseline in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Trial
184. Abstract 2985: Impact of PCI in Patients with Recent Onset Severe Angina or Stabilized ACS Treated with Optimal Medical Therapy: a COURAGE Trial High Risk Subset
185. Abstract 3511: Quality of Life in COURAGE Trial Patients with Diabetes
186. Abstract 2983: Sex Differences in Quality of Life and Health Status in the COURAGE Trial
187. Abstract 3507: Optimal Medical Therapy With or Without Percutaneous Coronary Intervention for Stable Coronary Artery Disease is Effective in Patients with Chronic Kidney Disease
188. Abstract 3506: Cost Effectiveness of Adding PCI to Optimal Medical Therapy in Patients with Stable Coronary Artery Disease: Economic Outcomes from the COURAGE Trial
189. Abstract 2449: Clinical Outcomes in Women with Stable Coronary Artery Disease Randomized to Optimal Medical Therapy With or Without PCI: Pre-Specified Subset Analysis of the COURAGE Trial
190. Foreword
191. The Effect of Antireflux Surgery on Esophageal Carcinogenesis in Patients With Barrett Esophagus
192. Office-Based Unsedated Small-Caliber Endoscopy Is Equivalent to Conventional Sedated Endoscopy in Screening and Surveillance for Barrett's Esophagus: A Randomized and Blinded Comparison
193. Incorporation of Nissen fundoplication in a rat model of duodenoesophageal reflux
194. The synergistic effect of heart disease and diabetes on self-management, symptoms, and health status
195. ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
196. Perioperative Morbidity Associated With Bariatric Surgery
197. Gastro-gastric Fistula in the Era of Divided Roux-en-Y Gastric Bypass: Strategies for Prevention, Diagnosis, and Management
198. Unsedated Small-Caliber Upper Endoscopy: An Emerging Diagnostic and Therapeutic Technology
199. Alterations in T-Cell Subset Frequency in Peripheral Blood in Obesity
200. Should patients with type 2 diabetes asymptomatic for coronary artery disease undergo testing for myocardial ischemia?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.